Want to see JP:7777 full AI Analyst Report?
3-D Matrix (7777) Stock Price & Analysis
7777 Stock Chart & Stats
- Day’s Range
- JPY 355.00 - JPY 375.00
- 52-Week Range
- JPY 293.00 - JPY 793.00
- Previous Close
- JPY 372.00
- Volume
- 200.00K
- Average Volume (3M)
- 1.32M
- Market Cap
- JPY 45.44B
- Enterprise Value
- JPY 41.01B
- Total Cash (Recent Filing)
- JPY 1.69B
- Total Debt (Recent Filing)
- JPY 600.00M
- Price to Earnings (P/E)
- 11.7
- Beta
- 1.79
- Next Earnings
- Dec 15, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Rapid and accelerating revenue growth indicates expanding commercialization of the company’s medical technology across its target markets. If sustained, a larger revenue base can improve operating leverage, support investment in product adoption, and provide a stronger foundation for durable earnings growth over the next several quarters.
Profitability Inflection
The shift from sizable losses to operating and net profitability is a meaningful improvement in the business model’s financial trajectory. Sustained profitability would strengthen internal funding capacity, reduce reliance on external capital, and demonstrate that growing commercial activity can translate into earnings rather than only higher sales.
Improved Capitalization
Materially lower debt and substantially higher equity improve financial resilience compared with the company’s earlier position. A stronger capitalization profile gives management more flexibility to fund commercialization, absorb operating volatility, and pursue growth without the same degree of balance-sheet pressure or financing dependence.
Bears Say
Weak Cash Conversion
Weak conversion of accounting profit into operating and free cash flow raises questions about the quality and repeatability of reported earnings. Continued cash generation will be important because small cash surpluses and a history of substantial burn could constrain reinvestment and increase the need for external funding.
Unproven Profit Durability
Although the latest period is profitable, the company has not yet established a long record of stable margins or earnings. Earlier deep losses and volatile results indicate that profitability may remain sensitive to execution and scale, making consistent performance across the next several reporting periods an important risk.
History Of Balance-sheet Stress
The recent balance-sheet recovery follows a period of significant financial stress rather than a consistently conservative funding profile. That history matters because renewed losses or weak cash generation could again pressure capitalization, limit strategic flexibility, and make disciplined funding essential to sustaining the turnaround.
3-D Matrix News
7777 FAQ
What was 3-D Matrix’s price range in the past 12 months?
What is 3-D Matrix’s market cap?
When is 3-D Matrix’s upcoming earnings report date?
How were 3-D Matrix’s earnings last quarter?
Is 3-D Matrix overvalued?
Does 3-D Matrix pay dividends?
What is 3-D Matrix’s EPS estimate?
How many shares outstanding does 3-D Matrix have?
What happened to 3-D Matrix’s price movement after its last earnings report?
Which hedge fund is a major shareholder of 3-D Matrix?
What is the TipRanks Smart Score and how is it calculated?
Company Description
3-D Matrix
3-D Matrix, Ltd. specializes in pioneering self-assembling peptide technology. Its flagship product, PuraMatrix, is an innovative self-assembling peptide hydrogel with diverse applications across medical fields, including regenerative medicine, cell therapy, advanced drug delivery systems, and surgical interventions. This Tokyo-based firm was established in 2004.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Toshihiko Amanuma
- Employees
- 129
- Website
- www.3d-matrix.co.jp
- Address
- Kojimachi HF Building, Tokyo, TY, 102-0083, JP
3-D Matrix (7777) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 6 | 14 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 0 | 0 | 12 |

